Study finds continued reduction in breast cancer incidence associated with longer use of raloxifene

November 30, 2004

Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.

The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that, in postmenopausal women with osteoporosis, 4 years of treatment with raloxifene was associated with a 72% reduction in breast cancer incidence compared with placebo. The Continuing Outcomes Relevant to Evista (CORE) trial was designed to examine the effect of an additional 4 years of treatment with raloxifene in the same group of women.

In the CORE trial, more than 4,000 women who had been part of the MORE trial continued taking either 60 mg/day of raloxifene, if they had been assigned to the raloxifene group in the MORE trial, or a placebo, if they had been assigned to the placebo group.

Silvana Martino, D.O., of the Cancer Institute Medical Group in Santa Monica, Calif., and colleagues report that, after the 4 years of the CORE trial, incidence of invasive breast cancer for women taking raloxifene was reduced by 59% compared with women taking the placebo, and incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66%. Over the entire 8 years of MORE and CORE, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% and 76%, respectively. There was no difference between the two groups in incidence of either ER-negative invasive breast cancer or noninvasive breast cancer. In both the MORE and CORE trials, there was a twofold increase in venous thromboembolic events, such as pulmonary embolism, among women taking raloxifene.

"[T]hese data demonstrate that the incidence of ER-positive invasive breast cancer continues to be reduced through 8 years of raloxifene treatment in postmenopausal women with osteoporosis," the authors write. "The effect of raloxifene on breast cancer incidence is currently being evaluated in postmenopausal women at high risk for heart disease in the Raloxifene Use for The Heart (RUTH) trial and in postmenopausal women at high risk for breast cancer in the STAR [Study of Tamoxifen and Raloxifene] trial."

In an editorial, Powel Brown, M.D., Ph.D., of the Baylor College of Medicine in Houston, and colleagues note that the effect of raloxifene treatment in the CORE trial may be confounded by several factors, but write that the results of the CORE and MORE trials support the conclusion that raloxifene reduces the risk of breast cancer. However, the authors write, "For women without osteoporosis who are at high risk of breast cancer, tamoxifen, in our opinion, remains the 'gold standard' chemoprevention agent to reduce the risk of breast cancer in high-risk pre- and postmenopausal women. We anticipate that the results of several large-scale chemoprevention trials will help clarify the role of raloxifene, as well as other hormonal agents, for breast cancer prevention."
-end-
Contacts:
  • Article: Darlene Ford, Cancer Institute Medical Group, 310-582-7907, dford@cimg.org
  • Editorial: Kimberlee Barbour, Office of Public Affairs, Baylor College of Medicine, 713-798-7971, kbarbour@bcm.tmc.edu

    Citations:
  • Article: Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. J Natl Cancer Inst 2004;96:1751-61.
  • Editorial: Kalidas M, Hilsenbeck S, Brown P. Defining the Role of Raloxifene for the Prevention of Breast Cancer. J Natl Cancer Inst 2004;96:1731-33.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.

    Journal of the National Cancer Institute

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.